Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

Archive ouverte

Jachiet, Vincent | Ricard, Laure | Hirsch, Pierre | Malard, Florent | Pascal, Laurent | Beyne-Rauzy, Odile | Peterlin, Pierre | Maria, Alexandre Thibault Jacques | Vey, Norbert | D’aveni, Maud | Gourin, Marie-Pierre | Dimicoli-Salazar, Sophie | Banos, Anne | Wickenhauser, Stefan | Terriou, Louis | de Renzis, Benoit | Durot, Eric | Natarajan-Ame, Shanti | Vekhoff, Anne | Voillat, Laurent | Park, Sophie | Vinit, Julien | Dieval, Céline | Dellal, Azeddine | Grobost, Vincent | Willems, Lise | Rossignol, Julien | Solary, Éric | Kosmider, Olivier | Dulphy, Nicolas | Zhao, Lin Pierre | Adès, Lionel | Fenaux, Pierre | Fain, Olivier | Mohty, Mohamad | Gaugler, Béatrice | Mekinian, Arsène

Edité par CCSD ; Springer Verlag -

International audience. Systemic inflammatory and autoimmune diseases (SIADs) occur in 10-20% of patients with myelodysplastic syndrome (MDS). Recently identified VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, associated with somatic mutations in UBA1 (Ubiquitin-like modifier-activating enzyme 1), encompasses a range of severe inflammatory conditions along with hematological abnormalities, including MDS. The pathophysiological mechanisms underlying the association between MDS and SIADs remain largely unknown, especially the roles of different myeloid immune cell subsets. The aim of this study was to quantitatively evaluate peripheral blood myeloid immune cells (dendritic cells (DC) and monocytes) by flow cytometry in MDS patients with associated SIAD (n = 14, most often including relapsing polychondritis or neutrophilic dermatoses) and to compare their distribution in MDS patients without SIAD (n = 23) and healthy controls (n = 7). Most MDS and MDS/SIAD patients had low-risk MDS. Eight of 14 (57%) MDS/SIAD patients carried UBA1 somatic mutations, defining VEXAS syndrome.Compared with MDS patients, most DC and monocyte subsets were significantly decreased in MDS/SIAD patients, especially in MDS patients with VEXAS syndrome. Our study provides the first overview of the peripheral blood immune myeloid cell distribution in MDS patients with associated SIADs and raises several hypotheses: possible redistribution to inflammation sites, increased apoptosis, or impaired development in the bone marrow.

Consulter en ligne

Suggestions

Du même auteur

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.

Archive ouverte | Mekinian, Arsene | CCSD

International audience

Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study

Archive ouverte | Péan de Ponfilly-Sotier, Marie | CCSD

International audience. Objectives: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML) are associated with systemic inflammatory and autoimmune diseases (SIADs) in 10-30% of cases. The aims ...

Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases

Archive ouverte | Zakine, Ève | CCSD

International audience

Chargement des enrichissements...